Clinical trials of potential vaccine for treating CD
Moderators: Rosie, Stanz, Jean, CAMary, moremuscle, JFR, Dee, xet, Peggy, Matthew, Gabes-Apg, grannyh, Gloria, Mars, starfire, Polly, Joefnh
Clinical trials of potential vaccine for treating CD
ImmusanT Inc., a privately owned biotechnology company in Cambridge, Ma, has begun clinical trails of a vaccine that it hopes will eliminate the toxic effects of gluten and allow people with celiac disease to resume a normal diet. The company intends to enroll a total of 114 people with CD in clinical trails of the vaccine, Nexvax2. in Australia, New Zealand and the United States. Nexvax2 combines three proprietary peptides to reprogram gluten-specfic T cells trigged by the patient's immune response to the protein. The goal is for Nexvax2 to restore celiac patients immune tolerance to gluten, reduce inflammation in the nutrient-absorbing villi that line the small intestine, return it to a healthy state and allow patients to eat a normal diet. " Taken from the Fall 2012 Healthy Villi Newsletter". Jon
